Prana Provides Update on IMAGINE Trial and Extension Trial for Alzheimer’s Disease
Melbourne – Monday 18th November, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) has today provided an update on the IMAGINE Phase 2 trial for Alzheimer’s Disease and is pleased to report that 29 patients of the 42 patients originally enrolled into the trial have now completed treatment.
The IMAGINE trial is a 12-month double-blind Phase 2 clinical trial of PBT2 in Alzheimer’s patients. Patients who have completed the full 12-month term of the IMAGINE trial are eligible for participation in an open-label Extension study. All participants in the Extension study will receive a 250mg once daily oral dose of PBT2 for an additional 12 months.
So far, 24 patients (of a possible 29) have continued on to the Extension trial, with a further patient currently being screened.
The company can also report that the Data Safety Monitoring Board (DSMB) has met for the fifth and final time and, consistent with all previous safety reviews, has made no recommendations to review or alter the original IMAGINE trial protocol.
The results of the IMAGINE Phase 2 trial are expected in March 2014.